Another clinical evaluation of Cytolog was carried out in the spring of 1993 by Dr. A. F, D.O. in Ohio (USA). It involved 17 patients with conditions that had proved unresponsive to conventional therapies. The reporting format was identical to the one previously listed. (Doctor's full names have been abbreviated for privacy)
The results of the two week study are outlined below.
(Experience has since shown that taking Cytolog Infopeptides for
30 days typically produces even more dramatic results)
(Experience has since shown that taking Cytolog Infopeptides for 30 days typically produces even more dramatic results)
From March of 1993 to March of 1996, monthly evaluations were carried out in remote areas of Central and South America. These settings were chosen because of the high incidence of viral diarrhea and viral respiratory conditions in infants and children.
Typical recovery intervals were as follows:
Throughout 1994, Dr. B. C., M.D., of Guatemala city was engaged in the evaluation of Cytolog. Besides the usual reports of efficacy with common viral and rheumatic conditions, Dr. C. described the positive response he observed in a patient with Kuru, a rare prion disease similar to Creutzfeldt-Jakob Syndrome.
In the summer of 1995, Dr. B. M., M.D., of La Loma Luz Adventist Hospital in the Cayo District of Belize reported the results of his use of Cytolog. Dr. M. observed benefit in patients suffering from many of the conditions listed above but added that when a woman he had diagnosed with lymphoma received the Infopeptide solution she experienced a dramatic reduction of two major clinical manifestations, fever and pain.
In the spring of 1996, Dr. E. T., M.D. of San Juan De Dios Hospital in Guatemala City, reported a number of successful applications of the Infopeptide supplement consistent with those previously reported. One particularly impressive case involved a 17 year old boy who had been admitted with post-chicken pox encephalitis. Immediately following the administration of Infopeptides his fever abated and his seizures ceased. A CAT scan taken during his 14 day hospitalization revealed no apparent damage associated with the event.
During this same time period, Dr. G D L., M.D., of Guatemala City, was reporting good success with his evaluation of the product. His pediatric practice provided him the opportunity to document, in a clinical setting, responses similar to those that had been observed earlier when the product was provided to fevering children in the remote jungle villages.
(Doctor's full names have been abbreviated for privacy)